Mitochondrial Disease Clinical Trial
Official title:
Anesthetic Effects in Mitochondrial Disease
Summary. At the present, the investigators do not have the perfect anesthetic for
mitochondrial patients. When possible, consideration should be given to the use of local
anesthetics in small amounts. When a general anesthetic is necessary, they each carry
significant risks and have been associated with poor outcomes. At present it is not possible
to eliminate one group as less safe than others. What is clear is that these patients must
be monitored more closely than other patients. The advent of the bispectral index (BIS)
monitor may allow us to monitor their depth of anesthesia more closely and thus expose these
patients only to the minimum amount of drug necessary to carry out the surgical procedure.
Purpose. The investigators hypothesize that specific mitochondrial diseases, in particular
those that decrease complex I function, make certain children hypersensitive to volatile
anesthetics. These same patients may be at increased risk for adverse outcomes following
general anesthesia. The specific aims of this application are:
1. Determine which molecular defects in mitochondrial function lead to alter sensitivity
to the VA sevoflurane.
2. Establish the relative safety of sevoflurane in treatment of patients with
mitochondrial disease.
The investigators plan to monitor patients with mitochondrial disease using expanded
measures of cardiovascular stability and measurements of brain electrical activity while
slowly inducing general anesthesia. The investigators will use those measurements to limit
the amount of anesthetic these patients receive in an attempt to minimize their risk. In
addition, the investigators will correlate their sensitivity to the type of mitochondrial
defect so that the investigators may be able to predict which patients are likely to have an
increased sensitivity.
n/a
Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02311257 -
Survey on Supplement Use in Mitochondrial Disease
|
N/A | |
| Completed |
NCT01642056 -
EPI-743 for Metabolism or Mitochondrial Disorders
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04419870 -
Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity During the COVID19 Pandemic
|
||
| Completed |
NCT00786539 -
Mitochondria Inborn Errors of Metabolism and ANT Defects in Mitochondria Diseases
|
||
| Active, not recruiting |
NCT02000284 -
Mitochondrial Dysfunction in Autism Spectrum Disorder
|
||
| Completed |
NCT04643249 -
Drug-drug Interaction Study of KL1333 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02544217 -
A Dose-escalating Clinical Trial With KH176
|
Phase 1 | |
| Completed |
NCT02154711 -
Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease
|
||
| Completed |
NCT01264471 -
Mechanisms of Mitochondrial Defects in Gulf War Syndrome
|
N/A | |
| Completed |
NCT00829270 -
Economic and Medical Evaluation of the Whole Mitochondrial DNA Screening by Surveyor and Mitochips Techniques
|
N/A | |
| Completed |
NCT02745938 -
GDF-15 as a Biomarker for Mitochondrial Disease
|
N/A | |
| Enrolling by invitation |
NCT01803906 -
Tissue Sample Study for Mitochondrial Disorders
|
||
| Completed |
NCT01776918 -
Energy Requirements in Mitochondrial Disease
|
N/A | |
| Completed |
NCT01301235 -
Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics in Patients With Mitochondrial Myopathy
|
N/A | |
| Completed |
NCT02985710 -
Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan
|
N/A | |
| Recruiting |
NCT05241262 -
Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
|
Phase 1 | |
| Completed |
NCT02678637 -
Calf Muscle Strength in Mitochondrial Diseases
|
N/A |